# Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

> **NCT03530293** · PHASE2 · TERMINATED · sponsor: **Neurocrine Biosciences** · enrollment: 81 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** Valbenazine
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03530293
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-17
- **Primary completion:** 2019-07-16
- **Final completion:** 2019-07-16
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03530293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03530293, "Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03530293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*